NCT03520231View on ClinicalTrials.gov

Study Comparing Denosumab With Standard Treatment in Urothelial Cancer Patients With Bone Metastases

PHASE2CompletedINTERVENTIONAL

Enrollment

6

Participants

Timeline

Start Date

September 4, 2018

Primary Completion Date

December 1, 2020

Study Completion Date

December 1, 2020

Conditions

Urothelial CarcinomaKidney CancerUreter CancerBladder Cancer

Interventions

DRUG

Denosumab

RANK Ligand Inhibitor

OTHER

Denosumab Placebo

Placebo

DRUG

Gemcitabine

Antineoplastic Agent

DRUG

Carboplatin

Antineoplastic Agent

DRUG

Cisplatin

Antineoplastic Agent

DIETARY_SUPPLEMENT

Calcium

Calcium Supplement

DIETARY_SUPPLEMENT

Vitamin D

Vitamin D Supplement

Trial Locations (1)

M5G 2M9

Princess Margaret Cancer Centre, Toronto

Sponsors

Collaborators (1)

All Listed Sponsors

collaborator

Amgen

INDUSTRY

lead

University Health Network, Toronto

OTHER